Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 protein

Clinical and Vaccine Immunology

Volumn 21, Issue 2, 2014, Pages 147-155

  Remy Ziller, Christelle ^a   Germain, Claire ^a,c   Spindler, Anita ^a   Hoffmann, Chantal ^a   Silvestre, Nathalie ^a   Rooke, Ronald ^a   Bonnefoy, Jean Yves ^a,b   Préville, Xavier ^a  

^a TRANSGENE S A   (France)

^b ElsaLys Biotech   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DRUG CARRIERS; FEMALE; HUMANS; IMMUNITY, CELLULAR; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS VACCINES; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 84893335678     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00678-13     Document Type: Article

References (40)

1. Jenkins M, Chiriva-Internati M, Mirandola L, Tonroy C, Tedjarati SS, Davis N, D'Cunha N, Tijani L, Hardwick F, Nguyen D, Kast WM, Cobos E. 2012. Perspective for prophylaxis and treatment of cervical cancer: an immunological approach. Int. Rev. Immunol. 31:3-21. http://dx.doi.org/10.3109/08830185.2011. 637254.
2. zur Hausen H. 2002. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2:342-350. http://dx.doi.org/10.1038/ nrc798.
3. Sanclemente G, Gill DK. 2002. Human papillomavirus molecular biology and pathogenesis. J. Eur. Acad. Dermatol. Venereol. 16:231-240. http://dx.doi.org/ 10.1046/j.1473-2165.2002.00419.x. (Pubitemid 34785320)
4. Rowhani-Rahbar A, Mao C, Hughes JP, Alvarez FB, Bryan JT, Hawes SE, Weiss NS, Koutsky LA. 2009. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 27:5612-5619. http://dx.doi.org/10.1016/ j.vaccine.2009.07.027.
5. Hildesheim A, Herrero R. 2007. Human papillomavirus vaccine should be given before sexual debut for maximum benefit. J. Infect. Dis. 196: 1431-1432. http://dx.doi.org/10.1086/522869. (Pubitemid 351411975)
6. Cid-Arregui A. 2009. Therapeutic vaccines against human papillomavirus and cervical cancer. Open Virol. J. 3:67-83. http://dx.doi.org/10.2174/ 1874357900903010067.
7. Rozendaal L, Walboomers JM, van der Linden JC, Voorhorst FJ, Kenemans P, Helmerhorst TJ, van Ballegooijen M, Meijer CJ. 1996. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int. J. Cancer 68:766-769. http://dx.doi.org/10.1002/(SICI)1097-0215(19961211)68:6〈766:: AID-IJC13〉3.0.CO;2-Z.
8. Moore RA, Santos EB, Nicholls PK, White KL, Anderson DM, Lloyd A, Topley P, Romanos M, Thomsen L, Parmar V, Walcott S, Gough GW, Stanley MA. 2002. Intraepithelial DNA immunisation with a plasmid encoding a codon optimised COPV E1 gene sequence, but not the wildtype gene sequence completely protects against mucosal challenge with infectious COPV in beagles. Virology 304:451-459. http://dx.doi.org/10.1006/viro.2002.1726. (Pubitemid 36069183)
9. Jensen ER, Selvakumar R, Shen H, Ahmed R, Wettstein FO, Miller JF. 1997. Recombinant Listeria monocytogenes vaccination eliminates papil-lomavirus- induced tumors and prevents papilloma formation from viral DNA. J. Virol. 71:8467-8474. (Pubitemid 27446427)
10. Egawa N, Nakahara T, Ohno SI, Narisawa-Saito M, Yugawa T, Fujita M, Yamato K, Natori Y, Kiyono T. 2012. The E1 protein of human papillomavirus type 16 is dispensable for maintenance replication of the viral genome. J. Virol. 86:3276-3283. http://dx.doi.org/10.1128/JVI.06450-11.
11. Acres B, Bonnefoy JY. 2008. Clinical development of MVA-based therapeutic cancer vaccines. Expert Rev. Vaccines 7:889-893. http://dx.doi.org/10.1586/ 14760584.7.7.889.
12. Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, Koralewski P, Breton JL, Stoelben E, Braun D, Debieuvre D, Lena H, Buyse M, Chenard MP, Acres B, Lacoste G, Bastien B, Tavernaro A, Bizouarne N, Bonnefoy JY, Limacher JM. 2011. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol. 12:1125-1133. http://dx.doi.org/10.1016/S1470-2045(11)70259-5.
13. Brun JL, Dalstein V, Leveque J, Mathevet P, Raulic P, Baldauf JJ, Scholl S, Huynh B, Douvier S, Riethmuller D, Clavel C, Birembaut P, Calenda V, Baudin M, Bory JP. 2011. Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am. J. Obstet. Gynecol. 204:169.e1-169.e8. http://dx.doi.org/10.1016/j.ajog.2010.09.020.
14. Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, Kingsman SM, Naylor S, Melcher A, Nicholls J, Wassan H, Habib N, Anthoney A. 2007. Vaccination of colorectal cancer patients with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin. Cancer Res. 13:4487-4494. http://dx.doi.org/10. 1158/1078-0432.CCR-07-0704. (Pubitemid 47219718)
15. Gomez CE, Najera JL, Krupa M, Esteban M. 2008. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr. Gene Ther. 8:97-120. http://dx.doi.org/10.2174/ 156652308784049363.
16. Harrop R, Ryan MG, Myers KA, Redchenko I, Kingsman SM, Carroll MW. 2006. Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated. Cancer Immunol. Immunother. 55:1081-1090. http://dx.doi.org/10.1007/s00262-005-0096-4. (Pubitemid 43800723)
17. Corona Gutierrez CM, Tinoco A, Navarro T, Contreras ML, Cortes RR, Calzado P, Reyes L, Posternak R, Morosoli G, Verde ML, Rosales R. 2004. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum. Gene Ther. 15:421-431. http://dx.doi.org/10.1089/10430340460745757. (Pubitemid 38639614)
18. Grandpre LE, Duke-Cohan JS, Ewald BA, Devoy C, Barouch DH, Letvin NL, Reinherz EL, Baden LR, Dolin R, Seaman MS. 2009. Immunogenicity of recombinant modified vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys. Vaccine 27:1549-1556. http://dx.doi.org/10.1016/j.vaccine.2009. 01.010.
19. Habersetzer F, Honnet G, Bain C, Maynard-Muet M, Leroy V, Zarski JP, Feray C, Baumert TF, Bronowicki JP, Doffoël M, Trépo C, Agathon D, Toh ML, Baudin M, Bonnefoy JY, Limacher JM, Inchauspé G. 2011. A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology 141:890-899.e4. http://dx.doi.org/ 10.1053/j.gastro.2011.06.009.
20. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. 1999. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213-219. http://dx.doi.org/10.1007/s002510050595. (Pubitemid 30099526)
21. Yasugi T, Vidal M, Sakai H, Howley PM, Benson JD. 1997. Two classes of human papillomavirus type 16 E1 mutants suggest pleiotropic conformational constraints affecting E1 multimerization, E2 interaction, and interaction with cellular proteins. J. Virol. 71:5942-5951. (Pubitemid 27304931)
22. Braun S, Thioudellet C, Rodriguez P, Ali-Hadji D, Perraud F, Accart N, Balloul JM, Halluard C, Acres B, Cavallini B, Pavirani A. 2000. Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice. Gene Ther. 7:1447-1457. http://dx.doi.org/10.1038/sj.gt.3301261.
23. Sutter G, Moss B. 1992. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. U. S. A. 89:10847-10851. http://dx.doi.org/10.1073/pnas.89.22.10847.
24. Cochran MA, Puckett C, Moss B. 1985. In vitro mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early and late regulatory signals. J. Virol. 54:30-37. (Pubitemid 15136841)
25. Masopust D, Ha S-J, Vezys V, Ahmed R. 2006. Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. J. Immunol. 177:831-839. (Pubitemid 44036583)
26. + T cells are more protective but slower to acquire a central-memory phenotype. J. Exp. Med. 203:919-932. http://dx.doi.org/10.1084/jem.20052237.
27. Penna A, Pilli M, Zerbini A, Orlandini A, Mezzadri S, Sacchelli L, Missale G, Ferrari C. 2007. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology 45:588-601. http://dx.doi.org/10.1002/hep.21541. (Pubitemid 46450610)
28. + T cells leads to reversible immune dysfunction. Nat. Med. 12:1198-1202. http://dx.doi.org/10.1038/nm1482.
29. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682-687. http://dx.doi.org/10.1038/nature04444. (Pubitemid 43237609)
30. Liu Y, Xu L, Jiang Y, Sun J, He X. 2007. Phenotypic and functional analysis of LCMV gp33-41-specific CD8 T cells elicited by multiple peptide immunization in mice revealed the up-regulation of PD-1 expression on antigen-specific CD8 T cells. Cell. Mol. Immunol. 4:431-437.
31. Rouse BT, Sarangi PP, Suvas S. 2006. Regulatory T cells in virus infections. Immunol. Rev. 212:272-286. http://dx.doi.org/10.1111/j.0105-2896. 2006.00412.x. (Pubitemid 44116714)
32. + T cell subsets identified by expression of IL-7 receptor alpha and CD62L. J. Immunol. 175:4686-4696.
33. Seder RA, Darrah PA, Roederer M. 2008. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8:247-258. http://dx.doi.org/10.1038/nri2274. (Pubitemid 351432801)
34. Fournillier A, Gerossier E, Evlashev A, Schmitt D, Simon B, Chatel L, Martin P, Silvestre N, Balloul JM, Barry R, Inchauspe G. 2007. An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses. Vaccine 25:7339-7353. http://dx.doi.org/10.1016/j.vaccine.2007.08. 020. (Pubitemid 47484019)
35. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. 2003. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77:4911-4927. http://dx.doi.org/10.1128/JVI.77.8.4911-4927.2003. (Pubitemid 36402840)
36. + T cells during viral infection: correlation with stable memory development. J. Gen. Virol. 83:2123-2133.
37. Geiben-Lynn R, Greenland JR, Frimpong-Boateng K, Letvin NL. 2008. Kinetics of recombinant adenovirus type 5, vaccinia virus, modified vaccinia Ankara virus, andDNAantigen expression in vivo and the induction of memory T-lymphocyte responses. Clin. Vaccine Immunol. 15:691-696. http://dx.doi.org/10. 1128/CVI.00418-07. (Pubitemid 351967048)
38. Stanley M, Pinto LA, Trimble C. 2012. Human papillomavirus vaccines - immune responses. Vaccine 30(Suppl 5):F83-F87. http://dx.doi.org/10.1016/j. vaccine.2012.04.106.
39. Kawana K, Adachi K, Kojima S, Kozuma S, Fujii T. 2012. Therapeutic human papillomavirus (HPV) vaccines: a novel approach. Open Virol. J. 6:264-269. http://dx.doi.org/10.2174/1874357901206010264.
40. Kojima S, Kawana K, Fujii T, Yokoyama T, Miura S, Tomio K, Tomio A, Yamashita A, Adachi K, Sato H, Nagamatsu T, Schust DJ, Kozuma S, Taketani Y. 2011. Characterization of gut-derived intraepithelial lymphocyte (IEL) residing in human papillomavirus (HPV)-infected intraepithelial neoplastic lesions. Am. J. Reprod. Immunol. 66:435-443. http://dx.doi.org/10.1111/j.1600-0897.2011. 01041.x.